11.1 Information on toxicological effects
Acute toxicity
Oral: No data available
LD50 Oral - 500.1 mg/kg
LC50 Inhalation - 4 h - 1.5 mg/l - dust/mist
Dermal: No data available
Skin corrosion/irritation
Remarks: No data available
Serious eye damage/eye irritation
Remarks: No data available
Respiratory or skin sensitization
Classified based on available data. For more details, see section 2
Germ cell mutagenicity
Classified based on available data. For more details, see section 2
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
May cause congenital malformation in the fetus.
Known human reproductive toxicant
Specific target organ toxicity - single exposure
Classified based on available data. For more details, see section 2
Specific target organ toxicity - repeated exposure
May cause damage to organs through prolonged or repeated exposure.
Aspiration hazard
Classified based on available data. For more details, see section 2
11.2 Additional Information
Lead salts have been reported to cross the placenta and to induce embryo- and feto- mortality. They also have teratogenic effect in some animal species. No teratogenic effects have been reported with exposure to organometallic lead compounds. Adverse effects of lead on human reproduction, embryonic and fetal development, and postnatal (e.g., mental) development have been reported. Excessive exposure can affect blood, nervous, and digestive systems. The synthesis of hemoglobin is inhibited and results in anemia. If left untreated, neuromuscular dysfunction, possible paralysis, and encephalopathy can result. Additional symptoms of overexposure include: joint and muscle pain, weakness of the extensor muscles (frequently the hand and wrist), headache, dizziness, abdominal pain, diarrhea, constipation, nausea, vomiting, blue line on the gums, insomnia, and metallic taste. High body levels produce increased cerebrospinal pressure, brain damage, and stupor leading to coma and often death.